solute carrier family 30 member 2Genealiases: PP12488 · TNZD · ZNT2 · ZnT-2
Q-omics provides the consensus-scored SLC30A2 profile across patient tissues and cancer cell-line models. SLC30A2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC30A2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SLC30A2 RNA expression shows 13,554 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where SLC30A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC30A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC30A2 survival associations across molecular data types. SLC30A2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC30A2 RNA expression–survival associations across cancer types. High SLC30A2 expression shows unfavorable associations in UCEC, LUSC, SKCM and ESCA, but favorable associations in ACC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC30A2 RNA expression.
This table summarizes SLC30A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC30A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC30A2 shows lower tumor expression in KIRC, KICH, KIRP and HNSC and higher tumor expression in UCEC and LUAD. The KIRC box plot shows higher SLC30A2 RNA expression in normal versus tumor tissue (log2 FC = −2.840, t-test p < 0.001).
This table shows molecular features associated with SLC30A2 in patient tissues and cancer cell lines. In patient samples, SLC30A2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC30A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and KIDNEY.
